La cadena de opciones muestra datos clave de las opciones de acciones de Rani Therapeutics Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Rani Therapeutics Hldgs..

Rani Therapeutics Hldgs (NASDAQ:RANI) Bolsa, Cadena de Opciones

Rani Therapeutics Hldgs

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Holdings Inc

News

Hedge Funds

General

FLUT

SPOT

ValueAct Holdings' Q3 2024 13F Filing Reveals Full Exits From Spotify, Fiserv, KKR & Co., New York Times With 1.34M Shares, And Flutter Entertainment

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.
What Happened: After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.
Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;
&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a>
Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. 
Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. 
Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
PLTR Price Action: Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Pershing Square Capital's Q3 2024 13F Filing Shows New Stakes In Brookfield Corp With 25.88M Shares, Nike With 13.24M Shares, And Seaport Entertainment Group With 2.09M Shares Each In Common Stock And Rights

RBLX

ValueAct Holdings' Q3 2024 13F Filing Indicates Increased Stakes In Walt Disney By 22% To 7.46M Shares And Roblox By 341% To 10.14M Shares

LLYVA

LLYVK

ValueAct Holdings' Q3 2024 13F Filing Shows New Stakes In Meta Platforms With 211.5K Shares, Live Nation Entertainment With 1.01M Shares, Visa With 373.6K Shares, Liberty Media Corp Series C With 1.34M Shares, And Liberty Media Corp Series A With 671.8K Shares

The loss is primarily attributable to a non-cash change in fair value of warrant liabilities related to common share price and warrant price appreciation during the quarter, production restart related operating expenses, and interest expense.

Earnings

Sable Offshore Reports Q3 Net Income Of $(255.6)M

Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat the analyst consensus estimate of $1.000 million by 92.60 percent. This is a 647.65 percent increase over sales of $257.606 thousand the same period last year.

Earnings Beats

MRKR

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Telsey Advisory Group analyst Dana Telsey maintains Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) with a Market Perform and maintains $2 price target.

Price Target

Analyst Ratings

LVLU

Telsey Advisory Group Maintains Market Perform on Lulus Fashion Lounge, Maintains $2 Price Target

XWEL

XWELL Q3 Revenue $8.4M Up From $7.5M YoY

NNOX

NVDA

RXRX

Nvidia 13F Shows Decreased Stake In Arm Holdings By 13% From 320,823 To 280,411 Shares; Decreased Stake In Recursion Pharmaceuticals By 12% From 57,797 To 50,784 Shares; Decreased Stake In Nano X Imaging Ltd By 17% From 437 To 362 Shares

Earnings Misses

POET

POET Technologies Q3 2024 GAAP EPS $(0.20) Misses $(0.090) Estimate

Contracts

Eaton Says It Has Been Selected By MDA Space To Deliver High-performance Propellant Storage Tanks

SERV

SOUN

Nvidia 13F Shows Increased Stake In Serve Robotics Inc By 308% From 7,267 To 29,629 Shares; Increased Stake In SoundHound AI By 18% From 6,836 To 8,065 Shares

WIIM

OKLO

Oklo shares are trading lower. The company reported Q3 financial results.

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform and raises the price target from $183 to $190.

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Raises Price Target to $190

ASML

MSCI

Third Point 13F Shows Exited Position In International Flavors & Fragrances, Previously Holding 1,300,000 Shares; Advance Auto Parts, Previously Holding 1,500,100 Shares; ASML Holding, Previously Holding 80,000 Shares; MSCI, Previously Holding 150,000 Shares; Micron Technology Inc, Previously Holding 275,000 Shares

Retractable Technologies Q3 Sales $10.3M, Flat YoY

Federal Reserve Chair Jerome Powell's unexpectedly hawkish remarks on Thursday sent markets into a tailspin. Major U.S. equity indices closed in the red, and the dollar soared for <a href="https://www.benzinga.com/topic/interest-rates">a fifth consecutive session</a>.
In a speech to Dallas business leaders, Powell highlighted the remarkable strength of the U.S. economy, indicating that there's no need for the Fed to &#8220;be in a hurry to lower rates.&#8221;
He reiterated the central bank's commitment to reaching its 2% inflation target, stressing the need for careful decision-making as inflation remains above desired levels.
He highlighted productivity gains, which he said have &#8220;grown faster over the past five years than at any point in the two decades preceding the pandemic,&#8221; positioning the U.S. economy as &#8220;the best-performing among major economies.&#8221;
Addressing the October <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">producer price index (PPI) uptick</a>, Powell labeled it &#8220;more than an upward bump&#8221; but maintained confidence in the trajectory toward the 2% inflation goal.
<h3 class="wp-block-heading">Markets Reassess Interest Rate Path: Traders Are Less Confident On A December Cut</h3>
Powell&#8217;s comments impacted the interest-rate market, with fed futures now reflecting a reduced likelihood of a 25-basis-point cut in December. 
The CME FedWatch tool shows the odds of such a move dropped to 58%, sharply down from around 80% earlier in the day.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.6%, fully erasing gains from last week&#8217;s rate cut. Energy was the only sector in positive territory, rising 0.4%, while industrials and health care led declines, each down 0.7%.
Top performers in the S&amp;P 500 included Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), which rose 12.8%, 8.7%, and 7.2%, respectively. Among the laggards were Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) and Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down 13.6% and 11.4%, respectively.
Tech stocks, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), declined 0.7%, marking a fourth consecutive loss. Blue chips followed by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.5%, while small caps in the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) underperformed, falling 1.3%.
The dollar continued to attract liquidity, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) logging a fifth consecutive gain, reaching levels last seen in late October 2023.
Treasury yields also rose, with the 10-year yield closing at 4.46%. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), marked its fifth straight loss.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was 1.7% lower in the past 24 hours to $88,013 at 5:21 p.m. ET, on track for its worst day in November.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">Trump&#8217;s Red Wave Pushes Emerging Market Stocks To 2-Month Lows: Volatility &#8216;Expected To Remain Elevated&#8217; </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Currency ETFs

Treasuries

Economics

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

FSLR

LDOS

SMCI

PowerShares DB US Dollar Index Bullish Fund

WYNN

Powell's Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hoth Therapeutics (HOTH – Research Report), Rewalk R...

Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rani Therapeutics Holdings (RANI – Research Report) today and set a price target...

Buy Rating Maintained for Rani Therapeutics: A Financial and Risk Analysis Amidst Recent Equity Financing

Investors have plenty to feel positive about. Inflation is easing, with the latest data showing an annualized rate of 2.4%, just shy of the Fed's t...

Oppenheimer Predicts up to 740% Rally for These 2 'Strong Buy' Stocks

Tevogen Bio, Rani Therapeutics, and Expion360 are the 3 Penny Stocks to watch on October 15, 2024, based on&nbsp;TipRanks' Penny Stock Screener too...

3 Penny Stocks to Watch Now, 10/15/24

Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering

Rani Therapeutics Holdings (RANI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Buy Rating Affirmed for Rani Therapeutics: Promising Developments in Oral Obesity Treatment with RaniPill™

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on RANI stock, giving a Buy rating on October 18. Michael Okunewitch has...

Rani Therapeutics: Innovative Oral Delivery System and Promising Obesity Treatment Potential Support Buy Rating

Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is ...

Rani Therapeutics Holdings options imply 12.6% move in share price post-earnings

Rani Therapeutics GAAP EPS of -$0.24 in-line

AVDL

HOTH

LFWD

RANI

TVGN

UCTT

XPON

Press Releases

Rani Therapeutics to Participate in August Investor Conferences

Financing

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Health Care

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

"Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology" more stocks inside….

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

Comments

Rani Therapeutics Hldgs

Rani Therapeutics Hldgs (RANI) Opciones

Rani Therapeutics Hldgs (NASDAQ:RANI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL